Enable® Aortic Sutureless Bioprosthesis Evaluation

NCT ID: NCT01720342

Last Updated: 2019-05-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

225 participants

Study Classification

OBSERVATIONAL

Study Start Date

2013-02-28

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The EASE Enable study is intended to collect additional data on the clinical outcomes of the Medtronic Enable® Aortic Bioprosthesis in "real world" patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The EASE Enable study is intended to characterize the clinical performance of the Medtronic Enable® aortic bioprosthesis in a post-market real-world setting.

This is a Non-randomized, prospective, non-interventional multi-center post-market release (PMR) study. Up to 800 subjects will be enrolled at up to 40 centers in Europe. After aortic valve replacement with the Enable® aortic bioprosthesis, each patient will have routine follow-up visits at the following intervals: at 30 days post-implant (at 30 days post-implant or prior to hospital discharge, whatever comes first), within 6 months following implantation, 1 year and annually thereafter up to 5 years post-implant.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Stenosis Aortic Valve Insufficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aortic valve stenosis, aortic valve insufficiency

Patients with aortic valve insufficiency and/or aortic valve stenosis who require AVR.

Aortic Valve Replacement surgery

Intervention Type PROCEDURE

Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aortic Valve Replacement surgery

Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Medtronic ATS 3f Enable® Aortic Bioprosthesis (Model 6000)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient with aortic valve stenosis, aortic valve insufficiency or a combination of the two.
* Patient requires replacement of his/her native aortic valve with a bioprosthesis with or without concomitant procedures.
* Patient is above the minimum age as required by local regulations to be participating in a clinical study.
* Patient is willing to return to the implant site for follow-up visits.
* Patient has been adequately informed of this clinical study and is willing to sign the patient Data Release Form.

Exclusion Criteria

* Patient requires replacement of two or more valves.
* Patient who underwent previous aortic valve replacement (AVR).
* Patient with native bicuspid aortic valve.
* Patient with active endocarditis or other systemic infection.
* Patient dilatation of the ascending aorta, deformations or irregular aortic annulus or ascending aorta geometry as seen via preoperative imaging.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Otto Dapunt, MD

Role: PRINCIPAL_INVESTIGATOR

LKH Universitätsklinik Graz, Austria

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Centre Hospitalier Régional Universitaire de Lille (CHRU)

Lille, , France

Site Status

Centre Hospitalier Universitaire de Saint-Etienne Hôpital Nord

Saint-Etienne, , France

Site Status

Universitätsklinikum Düsseldorf (UKD)

Düsseldorf, , Germany

Site Status

Medizinische Hochschule Hannover (MHH)

Hanover, , Germany

Site Status

Deutssches Herzzentrum Muenchen

Munich, , Germany

Site Status

Universitätsklinikum Münster (UKM)

Münster, , Germany

Site Status

Klinikum Oldenburg GmbH

Oldenburg, , Germany

Site Status

Universitätsklinikum Ulm

Ulm, , Germany

Site Status

Casa Di Cura Privata 'Montevergine' S.p.A.

Mercogliano, , Italy

Site Status

Ospedale Luigi Sacco

Milan, , Italy

Site Status

Azienda Complesso Ospedaliero S.Filippo Neri

Rome, , Italy

Site Status

Medisch Centrum Leeuwarden

Leeuwarden, , Netherlands

Site Status

Leids Universitair Medisch Centrum

Leiden, , Netherlands

Site Status

Hospital General Universitario Gregorio Marañón

Madrid, , Spain

Site Status

Hospiten Rambla

Santa Cruz de Tenerife, , Spain

Site Status

Inselspital

Bern, , Switzerland

Site Status

The James Cook University Hospital

Middlesbrough, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France Germany Italy Netherlands Spain Switzerland United Kingdom

References

Explore related publications, articles, or registry entries linked to this study.

Martens S, Sadowski J, Eckstein FS, Bartus K, Kapelak B, Sievers HH, Schlensak C, Carrel T. Clinical experience with the ATS 3f Enable(R) Sutureless Bioprosthesis. Eur J Cardiothorac Surg. 2011 Sep;40(3):749-55. doi: 10.1016/j.ejcts.2010.12.068. Epub 2011 Feb 20.

Reference Type BACKGROUND
PMID: 21342776 (View on PubMed)

Englberger L, Carrel TP, Doss M, Sadowski J, Bartus K, Eckstein FF, Asch FM, Martens S. Clinical performance of a sutureless aortic bioprosthesis: five-year results of the 3f Enable long-term follow-up study. J Thorac Cardiovasc Surg. 2014 Oct;148(4):1681-7. doi: 10.1016/j.jtcvs.2014.03.054. Epub 2014 Apr 4.

Reference Type BACKGROUND
PMID: 24787699 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

EASE Enable

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.